Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...

People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...

The cost of Eylea, an injectable medication for certain eye conditions, may vary based on your insurance coverage, treatment plan, and location of injections. Prior authorization may be required ...

Aflibercept 8mg (0.07mL of 114.3mg/mL); per vial; soln for oph intravitreal inj; preservative-free. A single-dose glass vial containing one Eylea HD 8 mg (0.07 mL of a 114.3 mg/mL solution); or A vial ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Eylea for the treatment of retinopathy of prematurity in preterm infants, according to a press ...

Eylea (aflibercept) injections can cause both mild and serious side effects, though serious side effects are rare according to clinical trials. Mild side effects include eye floaters, redness, and ...

The Food and Drug Administration has approved two new ways to use a higher-dose, longer-acting version of Regeneron Pharmaceuticals’ Eylea, positioning the medicine to better compete in the eye ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Four years after scoring an approval to treat diabetic retinopathy—a disease that strikes more than a third of those with diabetes and is the primary cause of blindness in the U.S.—Regeneron’s Eylea ...